Clinical Trial Update: Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients [Phase 4]

View source ↗

Summary

A Phase 4 study compares enteric-coated mycophenolate sodium with mycophenolate mofetil in de novo heart transplant patients, evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• Enteric-coated mycophenolate sodium (mycophenolate sodium)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Transplantation | Phase 4 | Status: COMPLETED